Comparative Safety of Three Temporary Embolic Agents in Transcatheter Arterial Embolization for Degenerative, Inflammatory, and Overuse Joint Disorders.

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology Pub Date : 2025-03-01 DOI:10.1016/j.jvir.2025.02.031

Tijmen A van Zadelhoff, Takatoshi Kubo, Masahiko Shibuya, Koichi Miyazaki, Masaya Nakata, Eiji Sugihara, Edwin H G Oei, Yuji Okuno

{"title":"Comparative Safety of Three Temporary Embolic Agents in Transcatheter Arterial Embolization for Degenerative, Inflammatory, and Overuse Joint Disorders.","authors":"Tijmen A van Zadelhoff, Takatoshi Kubo, Masahiko Shibuya, Koichi Miyazaki, Masaya Nakata, Eiji Sugihara, Edwin H G Oei, Yuji Okuno","doi":"10.1016/j.jvir.2025.02.031","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the safety and degree of pain relief of three rapidly biodegraded embolic materials, including imipenem/cilastatin (IPM/CS), quick-soluble gelatin sponge particles (QS-GSPs), and resorbable microsphere (RMs), in transcatheter arterial embolization (TAE) for degenerative, inflammatory, and overuse joint disorders.Materials and methods: Consecutive 431 patients, 527 joints with refractory overuse injuries, knee osteoarthritis, frozen shoulder, symptomatic rotator cuff tear, synovitis of the foot joints, and persistent pain after knee joint arthroplasty who underwent TAE between March 2020 and May 2023 were included in this retrospective study. IPM/CS, QS-GSPs, and RMs were used in 140 patients (176 TAEs), 136 patients (163 TAEs), and 155 patients (182 TAEs), respectively. Adverse events were monitored immediately after the procedure. Changes in pain numeric rating scale (NRS) were evaluated at 1, 3, and 6 months after TAE.Results: No serious adverse events were observed. Increased pain at the site of embolization after the procedure lasting more than 7 days occurred in 7.1%, 22%, and 5.8% of patients with IPM/CS, QS-GSPs, and RMs, respectively, more commonly in the elbow joint. The NRS improved from the baseline to 1, 3, and 6 months in IPM/CS patients (6.9±1.3 vs. 4.4±2.2, 3.6±2.3, and 3.1±2.4, respectively, all p <.0001), QS-GSPs patients (6.4±1.5 vs. 4.3±2.1, 3.6±2.2, and 3.0±2.1, respectively, all p <.0001), and RMs patients (7.0±1.3 vs. 4.4±2.2, 3.2±2.1, and 2.3±1.8, respectively, all p <.0001).Conclusions: IPM/CS, QS-GSPs, and RMs demonstrated acceptable safety profiles and effectively alleviated symptoms in TAE for degenerative, inflammatory, and overuse joint disorders.","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vascular and Interventional Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jvir.2025.02.031","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the safety and degree of pain relief of three rapidly biodegraded embolic materials, including imipenem/cilastatin (IPM/CS), quick-soluble gelatin sponge particles (QS-GSPs), and resorbable microsphere (RMs), in transcatheter arterial embolization (TAE) for degenerative, inflammatory, and overuse joint disorders.

Materials and methods: Consecutive 431 patients, 527 joints with refractory overuse injuries, knee osteoarthritis, frozen shoulder, symptomatic rotator cuff tear, synovitis of the foot joints, and persistent pain after knee joint arthroplasty who underwent TAE between March 2020 and May 2023 were included in this retrospective study. IPM/CS, QS-GSPs, and RMs were used in 140 patients (176 TAEs), 136 patients (163 TAEs), and 155 patients (182 TAEs), respectively. Adverse events were monitored immediately after the procedure. Changes in pain numeric rating scale (NRS) were evaluated at 1, 3, and 6 months after TAE.

Results: No serious adverse events were observed. Increased pain at the site of embolization after the procedure lasting more than 7 days occurred in 7.1%, 22%, and 5.8% of patients with IPM/CS, QS-GSPs, and RMs, respectively, more commonly in the elbow joint. The NRS improved from the baseline to 1, 3, and 6 months in IPM/CS patients (6.9±1.3 vs. 4.4±2.2, 3.6±2.3, and 3.1±2.4, respectively, all p <.0001), QS-GSPs patients (6.4±1.5 vs. 4.3±2.1, 3.6±2.2, and 3.0±2.1, respectively, all p <.0001), and RMs patients (7.0±1.3 vs. 4.4±2.2, 3.2±2.1, and 2.3±1.8, respectively, all p <.0001).

Conclusions: IPM/CS, QS-GSPs, and RMs demonstrated acceptable safety profiles and effectively alleviated symptoms in TAE for degenerative, inflammatory, and overuse joint disorders.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Vascular and Interventional Radiology 医学-核医学

CiteScore

4.30

自引率

10.30%

发文量

942

审稿时长

90 days

期刊介绍： JVIR, published continuously since 1990, is an international, monthly peer-reviewed interventional radiology journal. As the official journal of the Society of Interventional Radiology, JVIR is the peer-reviewed journal of choice for interventional radiologists, radiologists, cardiologists, vascular surgeons, neurosurgeons, and other clinicians who seek current and reliable information on every aspect of vascular and interventional radiology. Each issue of JVIR covers critical and cutting-edge medical minimally invasive, clinical, basic research, radiological, pathological, and socioeconomic issues of importance to the field.